Research programme: buprenorphine intranasal - Vernalis/Reckitt Benckiser

Drug Profile

Research programme: buprenorphine intranasal - Vernalis/Reckitt Benckiser

Alternative Names: IX-1004; IX-1005; V 1004; V 1005

Latest Information Update: 16 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Reckitt Benckiser; Vernalis
  • Developer Vernalis
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Drug abuse; Pain

Most Recent Events

  • 14 Mar 2007 Preclinical development is ongoing
  • 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis
  • 29 Mar 2005 Preclinical trials in Drug abuse in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top